Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Sponsor
Nurix Therapeutics, Inc.
Study ID
NCT07520006
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • NX-5948 — DRUG
    Administered orally once daily as a capsule
  • venetoclax — DRUG
    Administered orally once daily as a tablet per prescribing information
  • rituximab — DRUG
    Administered as an intravenous (IV) infusion per prescribing information
  • obinutuzumab — DRUG
    Administered as an IV infusion per prescribing information

Study Details

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Key Dates

Start date
May 31, 2026
Status verified
Apr 2026
Primary completion
May 31, 2033
Completion
May 31, 2033

Study Design

Enrollment
150 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: NX-5948 + venetoclax
  • Experimental: NX-5948 + venetoclax + rituximab
  • Experimental: NX-5948 + venetoclax + obinutuzumab

Primary Outcome Measure

Number of participants with treatment-emergent adverse events [ Time Frame: Up to approximately 7 years ]

Central Contacts

Related Studies